Do you want to read an article? Please log in or register.
Kirsten Rat Sarcoma Virus Mutations Effect On Tumor Doubling Time And Prognosis Of Solid Dominant Stage I Lung Adenocarcinoma
Lung Cancer
RECOMMENDED
Related content
Lung Cancer
Immunotherapy Improves Clinical Outcome in Kirsten Rat Sarcoma Virus-Mutated Patients with Unresectable Non-Small Cell Lung Cancer Stage III: A Subcohort Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR)
J Clin Med
Ruznic E, Klebermass M, Zellinger B, Langer B, Grambozov B, Purevdorj A, Karner J, Gruber G, Stana M, Minasch D, Kirchhammer K, Steffal C, Stranzl H, Moosbrugger R, Feurstein P, Dieckmann K, Zehentmayr F, ALLSTAR Group
doi: 10.3390/jcm14030945
Lung Cancer
Impact of TP53 Co-Mutation on Clinicopathological Features, Prognosis, Recurrence Patterns, and the Efficacy of EGFR-TKI Treatment After Recurrence in Resected Early-Stage EGFR-Mutated Lung Adenocarcinoma
Clin Lung Cancer
Masuda T, Katsumata S, Isaka M, Serizawa M, Kawata T, Asami M, Yamaguchi D, Matsushima K, Hayasaka K, Kojima H, Yokomakura N, Konno H, Nagashima T, Urakami K, Yamaguchi K, Ohde Y
doi: 10.1016/j.cllc.2025.04.009
Lung Cancer
Tumor-Agnostic Circulating Tumor DNA Analysis as a Comprehensive Predictive Biomarker of Recurrence after Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer
Clin Lung Cancer
Nakamura M, Kageyama SI, Hirata H, Ohira M, Sakai SA, Hakozaki Y, Hojo H, Fujisawa T, Yamashita R, Haeno H, Kanai A, Suzuki Y, Yamaguchi M, Tsuchihara K, Zenda S
doi: 10.1016/j.cllc.2025.09.013
Lung Cancer
Pattern of brain metastases and survival in lung adenocarcinoma with KRAS or EFGR mutation
Lung Cancer
Faehling M, Fallscheer S, Schmiederer J, Sträter J, Christopoulos P, Lengerke C, Seifarth H
doi: 10.1016/j.lungcan.2025.108803
Lung Cancer
Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial
Lancet Respir Med
Shi Y, Wu L, Ji Y, Chen G, Li B, Bi M, Yang R, Miao L, Zhang G, Gao H, Sun L, Zhang M, Cang S, Sun M, Yao W, Pan Z, Cui J, Xiao Y, Wang Q, NCT04143607 Study Group
doi: 10.1016/S2213-2600(25)00121-3
Lung Cancer
Cost-effectiveness of adjuvant alectinib in the treatment of patients with resected stage IB-IIIA ALK-positive non-small lung cancer in France, based on the ALINA study
Lung Cancer
Supiot R, Gherardi A, du Manoir de Juaye L, Doghri O, Sivignon M, Duruisseaux M, Chouaid C
doi: 10.1016/j.lungcan.2025.108885
RECOMMENDED
Lung Cancer
Real World Effectiveness of Durvalumab in Stage III Unresectable Non-small Cell Lung Cancer: What is the Role of PD-L1 Expression?
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Kalkhoran HA, Verschueren MV, Peters BJM, van de Garde EMW, Smit EF, Bohringer S, Cohen D, Gulikers JL, Codrington H, Guchelaar HJ, Visser LE, Zwaveling J
doi: 10.1016/j.cllc.2025.07.009
Lung Cancer
Predictors of Multidisciplinary Tumor Board Adherence in Stage III Non-Small-Cell Lung Cancer Patients From a Large Multicenter Study
Clin Lung Cancer
Koster KL, Yohasenan S, Pakmak AS, Mark M, Metaxas Y, Lips C, Hitz F, Leskow P, Ludwig C, Putora PM, Glatzer M, Schneider T, Caviezel C, Mader T, Mousavi M, Blum M, Früh M, Joerger M
doi: 10.1016/j.cllc.2025.05.010
Lung Cancer
Modeling brain metastases in cost effectiveness analysis of atezolizumab for extensive stage small cell lung cancer
Sci Rep
Chen HL, Chueh CH, Huang WM, Chan SH, Cheng HH, Chiang SC, Wu CE, Wen YW, Tsai YW
doi: 10.1038/s41598-025-22966-4